Influence of isradipine and spirapril on left ventricular hypertrophy and resistance arteries

Hypertension

Volumn 28, Issue 3, 1996, Pages 450-456

  Thürmann, Petra A ^a   Stephens, Nicola ^b   Heagerty, Anthony M ^b   Kenedi, Peter ^c   Weidinger, Gottfried ^d   Rietbrock, Norbert ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c Medizinisch Geriatrische Klinik   (Germany)

^d Product Development   (Germany)

Author keywords

antihypertensive therapy; hypertension, essential; hypertrophy, left ventricular; resistance vessels

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ISRADIPINE; NORADRENALIN; SPIRAPRIL;

ANTIHYPERTENSIVE THERAPY; ARTERY DIAMETER; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; TREATMENT OUTCOME;

EID: 0029815052     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.28.3.450     Document Type: Article

References (55)

1. Messerli FH. Clinical determinants and consequences of left ventricular hypertrophy. Am J Med. 1983;75(3A):51-56.
2. Folkow B. The Fourth Volhard Lecture: Cardiovascular structural adaptation: its role in the initiation and maintenance of primary hypertension. Clin Sci Mol Med. 1978;55:3S-22S.
3. Dahlöf B. Factors involved in the pathogenesis and consequences of hypertensive hypertrophy: a review. Drugs. 1988;35(suppl 5):6-26.
4. Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol. 1979; 44:959-963.
5. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322:1561-1566.
6. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991; 114:345-352.
7. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
8. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
9. MacMahon S, Collins G, Rautaharju P, Cutler J, Neaton J, Prineas R, Crow R, Stamler J. Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the multiple risk factor intervention trial. Am J Cardiol. 1989;63:202-210.
10. Kannel WB, D'Agostino RB, Levy D, Belanger AJ. Prognostic significance of regression of left ventricular hypertrophy. Circulation. 1988;78(suppl II):II-89. Abstract.
11. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1095.
12. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347-467.
13. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension: dual processes of remodeling and growth. Hypertension. 1993;21:391-397.
14. Brush JE, Cannon RO, Schenke WH, Bonow RO, Leon MB, Maron BJ, Epstein SE. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319:1302-1307.
15. Schwartzkopff B, Motz W, Knauer S, Frenzel H, Strauer BE. Morphometric investigation of intramyocardial arterioles in right septal endomyocardial biopsy of patients with arterial hypertension and left ventricular hypertrophy. J Curdiovasc Pharmacol. 1992;20(suppl 1): S12-S17.
16. Boudier HAJS, van Bortel LMAB, De Mey JGR. Remodeling of the vascular tree in hypertension: drug effects. Trends Pharmacol Sci. 1990;11:240-245.
17. Heagerty AM, Bund SJ, Aalkjaer C. Effects of drug treatment on human resistance arteriole morphology in essential hypertension: direct evidence for structural remodelling of resistance vessels. Lancet. 1988;2:1209-1212.
18. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83-91.
19. Aalkjaer C, Eiskjaer H, Mulvany MJ, Jespersen B, Kjaer T, Sorensen SS, Pedersen EB. Abnormal structure and function of isolated subcutaneous resistance vessels from essential hypertensive patients despite antihypertensive treatment. J Hypertens. 1989;7:305-310.
20. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension. 1995;4:474-481.
21. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Mørn B, Mulvany M, Thygesen C, Pedersen OL. Normalization of resistance artery structure and left ventricular morphology with a perindopril-based regimen. Can J Cardiol. 1994;10(suppl D):30D-32D.
22. Motz W, Strauer BE. Organ protection: benefit from antihypertensive treatment? J Cardiovasc Pharmacol. 1994;24(suppl 2):S50-S54.
23. Levy BI, Safar ME. Remodeling of the vascular system in response to hypertension and drug therapy. Clin Exp Pharmacol Physiol. 1992;19(suppl 19):33-37.
24. Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension. 1991;18(suppl II):II-100-II-105.
25. Brilla CG, Maisch B, Weber KT. Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Invest. 1993;71:S35-S41.
26. Clozel JP, Kuhn H, Hefti F. Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med. 1989;87(suppl 6B):92S-95S.
27. Messerli FH. Effects of calcium channel blockade on cardiac repercussions of long-standing hypertension. J Cardiovasc Pharmacol. 1988;12(suppl 6):S44-S47.
28. Sano T, Tarazi C. Differential structural responses of small resistance vessels to antihypertensive therapy. Circulation. 1987;75:618-626.
29. Kobayashi H, Sano T, Tarazi RC, Fouad-Tarazi FM. Effects of antihypertensive drugs on heart and resistance vessels. Cardiovasc Res. 1990;24:137-143.
30. Agabiti-Rosei E, Muiesan ML, Geri A, Romanelli G, Montani G, Muiesan G. Relation between cardiac hypertrophy and forearm vascular structural changes before and during long-term antihypertensive treatment. Am J Med. 1988;84(suppl 3A):125-128.
31. Fitscha P, Meisner W, Hitzenberger G. Antihypertensive effects of isradipine and captopril as monotherapy or in combination. Am J Hypertens. 1991;4:151S-153S.
32. Hayduk K, Schardt F, Sierakowski B, Weidinger G, Welzel D. Single daily administration of spirapril in the treatment of essential hypertension. Blood Pressure. 1994;3(suppl 2):41-46.
33. Dahlöf B. Hemodynamic response, safety, and efficacy of isradipine in the treatment of essential hypertension. Am J Med. 1989;86(suppl 4A):19-26.
34. Arita M, Horinaka S, Frohlich ED. Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats. J Hypertens. 1993;11:951-959.
35. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986; 57:450-458.
36. Aalkjaer C, Pedersen EB, Danielsen H, Fjeldborg O, Jespersen B, Kjaer T, Sorensen SS, Mulvany MJ. Morphological and functional characteristics of isolated resistance vessels in advanced uremia. Clin Sci. 1986;71:657-663.
37. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
38. Mitteilungen der Deutschen Gesellschaft für Herz- und Kreislaufforschung e.V. Empfehlungen für die Doppler-Echokardiographie In der Erwachsenen-Kardiologie. Z Kardiol. 1990;79:312-313.
39. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res. 1977;41:19-26.
40. Bielen EC, Fagard RH, Lijnen PJ, Tjandra-Maga TB, Vebesselt R, Amery AK. Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension. Am J Cardiol. 1992;69:1200-1206.
41. Agabiti-Rosei E, Muiesan ML, Rizzoni D, Zulu R, Calebich S, Castellano M, Cavaliere G, Nordio G, Pasini F, Zuccato F. Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension. J Cardiovasc Pharmacol. 1994;24(suppl A): S37-S43.
42. Schulte K-L, Meyer-Sabellek W, Liederwald K, van Gemmeren D, Lenz T. Gotzen R. Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine. Am J Cardiol. 1992;70:468-473.
43. Dahlöf B, Hansson L. Regression of left ventricular hypertrophy in previouslv untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens. 1992;10:1513-1524.
44. Franz I-W, Ketelhut R, Behr U, Tönnesmann U. Time course of reduction in left ventricular mass during long-term antihypertensive therapy. J Hum Hypertens. 1994;8:191-198.
45. Modena MG, Mattioli AV, Parato VM, Mattioli G. Effectiveness of the antihypertensive action of lisinopril on left ventricular mass and diastolic filling. Eur Heart J. 1992;13:1540-1544.
46. Modena MG, Mattioli AV, Parato VM, Mattioli G. Effect of anti-hypertensive treatment with nitrendipine on left ventricular mass and diastolic filling in patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1992;19:148-153.
47. Muiesan ML, Agabiti-Rosei E, Romanelli G, Alari G, Barbier P, Fiorentini C, Muiesan G. Left ventricular systolic function in relation to withdrawal of different pharmacological treatments in hypertensives with left ventricular hypertrophy. J Hypertens. 1988;6(suppl 4):S97-S100.
48. Hartford M, Wendelhag I, Berglund G, Wallentin I, Ljungman S, Wikstrand J. Cardiovascular and renal effects of long-term antihypertensive treatment. JAMA. 1988;259:2553-2557.
49. Haberbosch W, De Simone R, Dietz R, Waas W, Tillmanns H, Kübler W. Improvement of diastolic filling in hypertensive patients treated with cilazapril. J Cardiovasc Pharmacol. 1991;17(suppl 2): S159-S162.
50. Shahi M, Thom S, Poulter N, Sever PS, Foale RA. Regression of hypertensive left ventricular hypertrophy and ventricular diastolic function. Lancet. 1990;336:458-461.
51. Keeley FW, Elmoselhi A, Leenen FHH. Effects of antihypertensive drug classes on regression of connective tissue components of hypertension. J Cardiovasc Pharmacol. 1991;17(suppl 2):S64-S69.
52. Jennings GL, Murray DE, Korner PI. Effect of prolonged treatment on haemodynamics of essential hypertension before and after autonomic block. Lancet. 1980;2:166-169.
53. Sivertsson R, Hansson L. Effects of blood pressure reduction on the structural vascular abnormality in skin and muscle vascular beds in human essential hypertension. Clin Sci Mol Med. 1976;51:77s-79s.
54. Agabiti-Rosei E, Rizzoni D, Castellano M, Porteri E, Zulli R, Muiesan ML, Bettoni G, Salvetti M, Muiesan P, Giulini SM. Media:lumen ratio in human small resistance arteries is related to forearm minimal vascular resistance. J Hypertens. 1995;13:341-347.
55. Sihm I, Schroeder AP, Aalkjaer C, Holm M, Morn B, Mulvany MJ, Thygesen K, Lederballe O. Effect of antihypertensive treatment on subcutaneous arteries: a comparison between isradipine and thiazide based regimens in essential hypertension. Eur Heart J. 1994; 15(suppl):347. Abstract.